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Premature senescence involving p53
and p16 is activated in response
to constitutive MEK/MAPK
mitogenic signaling
Athena W. Lin,1 Marta Barradas,2 James C. Stone,3 Linda van Aelst,1 Manuel Serrano,2
and Scott W. Lowe1,4
1Cold Spring Harbor Laboratory, Cold Spring Harbor, New York 11724 USA; 2Department of Immunology and Oncology,
Centro Nacional de Biotecnologa´, Cantoblanco, Madrid E-28049, Spain; 3Department of Biochemistry, University of Alberta,
Edmonton, Alberta T6G 2H7, Canada
Oncogenic Ras transforms immortal rodent cells to a tumorigenic state, in part, by constitutively transmitting
mitogenic signals through the mitogen-activated protein kinase (MAPK) cascade. In primary cells, Ras is
initially mitogenic but eventually induces premature senescence involving the p53 and p16INK4a tumor
suppressors. Constitutive activation of MEK (a component of the MAPK cascade) induces both p53 and p16,
and is required for Ras-induced senescence of normal human fibroblasts. Furthermore, activated MEK
permanently arrests primary murine fibroblasts but forces uncontrolled mitogenesis and transformation in
cells lacking either p53 or INK4a. The precisely opposite response of normal and immortalized cells to
constitutive activation of the MAPK cascade implies that premature senescence acts as a fail-safe mechanism
to limit the transforming potential of excessive Ras mitogenic signaling. Consequently, constitutive MAPK
signaling activates p53 and p16 as tumor suppressors.
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Cancer arises through the accumulation of genetic
changes that each enhances the growth or survival of
developing tumor cells (Fearon and Vogelstein 1990).
Perhaps the simplest experimental model of this mul-
tistep process involves transformation of primary cul-
tures by ras oncogenes (Weinberg 1989; Ruley 1990). On-
cogenic Ras transforms most immortal rodent cells to a
tumorigenic state, whereas transformation of primary
cells requires either a cooperating oncogene (e.g., E1A) or
the inactivation of tumor suppressors such p53 or INK4a
(Gallimore et al. 1986; Tanaka et al. 1994; Serrano et al.
1996). Importantly, these transforming interactions have
been validated in animal models and, in several in-
stances, the genetic changes that cooperate with ras in
primary cells are comutated with ras in spontaneous tu-
mors (Fearon and Vogelstein 1990; Burns et al. 1991;
Kemp et al. 1993; Linardopoulos et al. 1995; Chin et al.
1997).
Despite the widespread use of oncogene cooperation
assays to model genetic interactions during tumorigen-
esis, a biological explanation for this phenomenon is
only now emerging. Primary rodent and human cells un-
dergo a limited number of cell doublings in culture and
then undergo a process of cellular senescence (Hayflick
1965). When expressed alone, most oncogenes that co-
operate with ras in transformation extend cellular life
span in human cells, and facilitate the establishment of
primary rodent cells into immortal cell lines (Ruley
1990). This observation suggested that oncogenic Ras re-
quires ‘immortalizing’ changes to promote oncogenic
transformation; these could occur spontaneously in im-
mortal cell lines or be provided by a cooperating onco-
gene (for review, see Weinberg 1997). At the same time,
other studies suggested that normal cells actively resist
transformation by Ras (Franza et al. 1986; Hirakawa and
Ruley 1988), implying that cooperating oncogenes inter-
fere with natural anti-oncogenic defenses.
We demonstrated recently that prolonged expression
of oncogenic Ras induces a permanent cell-cycle arrest in
primary human and rodent fibroblasts that is phenotypi-
cally indistinguishable from cellular senescence (Serrano
et al. 1997). Consequently, these studies explain the re-
quirement for immortalizing changes in ras transforma-
tion assays, and identify a mechanism whereby normal
cells actively counter ras’ transforming potential. For ex-
ample, because immortal rodent cell lines have already
lost aspects of the senescence program, they are readily
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transformed by oncogenic Ras alone. Similarly, immor-
talizing oncogenes disrupt the senescence program re-
tained in primary cells; hence, such changes interfere
with the ability of oncogenic Ras to provoke senescence.
In either case, cells escape normal growth controls that
actively limit transformation by Ras. Consequently, pre-
mature senescence may function as a bona fide mecha-
nism of tumor suppression (Serrano et al. 1997; for re-
view, see Weinberg 1997).
Consistent with this view, p53 and p16INK4a appear
critical for premature senescence induced by oncogenic
Ras (Serrano et al. 1997). Both p53 and INK4a are mu-
tated at high frequency in many tumor types, implying
that their action is central to tumor development. Nev-
ertheless, the precise circumstances in which either is
engaged to function as tumor suppressors remain poorly
understood. p53 can promote cell-cycle arrest or apopto-
sis in response to a variety of cellular stresses, including
DNA damage and hypoxia (Kastan 1993; Graeber et al.
1996). In both settings, cells acquiring p53 mutations
have a selective advantage over their p53-normal coun-
terparts. p16 increases gradually as cells proceed towards
senescence (Alcorta et al. 1996; Zindy et al. 1997). Con-
sequently, loss of p16 might uncouple the cell-cycle ma-
chinery from a cell-doubling clock, allowing developing
tumor cells to proliferate beyond their normal life span.
The fact that oncogenic Ras activates p53 and p16 pro-
vides an additional explanation for their action as tumor
suppressors: p53 and p16 act in a compensatory mecha-
nism that suppresses Ras-induced transformation.
Hence, cells acquiring p53 and INK4a mutations would
tolerate ras mutations occurring early in tumor develop-
ment (Serrano et al. 1996).
In immortal rodent lines, transformation by oncogenic
Ras involves its ability to bind and activate a series of
effector proteins, including Raf-1, phosphoinositide
3-OH kinase [PI(3)K], and Ral.GDS (Van Aelst et al. 1993;
Rodriguez-Viciana et al. 1994; Spaargaren and Bischoff
1994). Each of these proteins, in turn, activates distinct
downstream targets, thereby producing different aspects
of the transformed phenotype (for review, see Katz and
McCormick 1997). For example, the Ras–Raf interaction
initiates the mitogen-activated protein kinase (MAPK)
cascade, which involves the sequential activation of a
series of protein kinases that transmit mitogenic signals
to nuclear transcription factors (Chen et al. 1992; Gille et
al. 1995). These kinases include Raf-1, the MEKs (MEK1
and MEK2), and the MAPKs (ERK1 and ERK2). In con-
trast, the ability of Ras to activate PI(3)K promotes mem-
brane ruffling (Joneson et al. 1996; Rodriguez-Viciana et
al. 1997), perhaps through Rac and Rho (for review, see
Van Aelst and D’Souza-Schorey 1997), and may also sup-
press apoptosis through activation of Akt/PKB (for re-
view, see Downward 1998). Finally, the Ral.GDS pro-
teins act as exchange factors that can activate the Ral
family of small GTPases (Spaargaren and Bischoff 1994)
which, in turn, can regulate phospholipase D (Jiang et al.
1995). Although each of these effector pathways contrib-
utes to the transforming activity of Ras in immortal ro-
dent fibroblasts (Khosravi-Far et al. 1995, 1996; White et
al. 1995; Urano et al. 1996; Rodriguez-Viciana et al.
1997), activation of the MAPK cascade is clearly suffi-
cient (Cowley et al. 1994; Mansour et al. 1994; Bottorff et
al. 1995; Stang et al. 1997).
Almost all of the studies examining Ras signaling in
mammalian systems have utilized immortal or tumor-
derived lines harboring unknown genetic alterations. Be-
cause premature senescence induced by Ras is restricted
largely to nonimmortal cells (Serrano et al. 1997), Ras
might signal premature senescence through an uniden-
tified pathway lost during the immortalization process.
Alternatively, Ras could promote premature senescence
through a known effector pathway or by activating a
combination of effector pathways. In the current study,
we identified the effector pathway responsible for Ras-
induced senescence. We find that Ras induces senes-
cence in normal cells through the primary mechanism
whereby it forces uncontrolled proliferation and trans-
formation in immortal cell lines. These results have im-
portant implications for our understanding of oncogene
cooperation, tumor suppression, and the regulation of
cellular senescence.
Results
Oncogenic Ras is initially mitogenic in normal diploid
human fibroblasts
Microinjection of oncogenic ras into human diploid fi-
broblasts induces S-phase entry (Lumpkin et al. 1986).
On the other hand, retroviral transduction of oncogenic
ras into human fibroblasts provokes permanent cell-
cycle arrest (Serrano et al. 1997). These observations
raise the possibility that the initial effect of Ras is forced
proliferation and, only later, cell-cycle arrest. Therefore,
the immediate and long-term consequences of oncogenic
Ras expression were examined in the same population of
normal diploid human IMR90 fibroblasts. In this and
subsequent experiments, oncogenic ras (H-RasV12) was
introduced into whole-cell populations using high-titer
retroviral vectors coexpressing a selectable marker. After
a brief selection to eliminate uninfected cells, cells were
plated for all assays described below (designated day −1).
Using this protocol, the percentage of transduced cells
ranged between 70% and 90% as estimated in parallel
infection with viruses expressing a lacZ reporter (data
not shown).
To examine the proliferation properties of Ras-ex-
pressing populations, [3H]thymidine and BrdU incorpo-
ration were measured shortly after ras transduction (48–
72 hr postinfection) in the presence and absence of se-
rum. In normal growth conditions (10% serum), vector
and Ras-expressing cells incorporated similar amounts of
[3H]thymidine (Fig. 1A). As expected, transfer of vector-
containing cells to low serum for 24 hr resulted in a
marked reduction in [3H]thymidine incorporation. By
contrast, Ras-expressing cells continued to incorporate
high levels of [3H]thymidine even after serum depletion.
Similarly, Ras-expressing cells placed in low serum in-
corporatated twice as much BrdU as cells containing an
MAPK cascade, senescence, and tumor suppression
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empty vector (Fig. 1B). Initially, proliferation in the pres-
ence of oncogenic Ras was accompanied by morphologi-
cal changes characteristic of constitutive Ras activity in
immortal cells, becoming small and refractile with thin
cytoplasmic projections (Fig. 1C). Only later do Ras-ex-
pressing cells acquire the characteristic senescent mor-
phology (Fig. 1C; see also Serrano et al. 1997). Therefore,
the immediate consequences of oncogenic Ras expres-
sion are forced proliferation, implying that cell-cycle ar-
rest is an antiproliferative cellular response.
Ras effectors and cell-cycle arrest
As a first step in identifying the Ras-signaling pathway(s)
required for premature senescence, we exploited a series
of Ras ‘effector loop’ mutants that interact preferentially
with specific Ras effector proteins (White et al. 1995;
Joneson et al. 1996). For example, H–RasV12/S35 binds
preferentially to Raf-1 and activates MAPK but has no
effect on membrane ruffling (White et al. 1995). In con-
trast, H-RasV12/C40 associates with PI(3)K and pro-
motes membrane ruffling and cell survival but does not
bind Raf-1 or induce mitogenesis (Joneson et al. 1996;
Rodriguez-Viciana et al. 1997). H-RasV12/G37 binds
Ral.GDS but fails to bind Raf-1 or PI(3)K (White et al.
1995). IMR90 human fibroblasts were infected with ret-
roviruses expressing individual Ras mutants, and cell
proliferation was determined by assessing relative cell
accumulation at various times postplating (Serrano et al.
1997).
Consistent with previous results, constitutive expres-
sion of oncogenic Ras induced cell-cycle arrest at sub-
confluent densities and in the presence of serum,
whereas cells harboring the empty vector grew exponen-
tially to confluence (Fig. 2A). Cell populations express-
ing the H–RasV12/G37 or H-RasV12/C40 mutants failed
to arrest, suggesting that neither the Ras–PI(3)K interac-
tion nor the Ras–Ral.GDS interaction is sufficient to in-
Figure 1. Oncogenic Ras is initially mito-
genic in primary fibroblasts. (A) [3H]thymi-
dine incorporation assay using IMR90 cell
populations containing empty vector (V) or
H–RasV12 (R). Twenty-four hours postin-
fection, 2 × 14 of the indicated cells were
plated and grown in medium containing
10% FBS or 0.5% FBS for 24 hr followed by
a 3H]thymidine pulse. Values were normal-
ized to those obtained from control popu-
lations in 10% serum; the average and stan-
dard deviation of three measures are
shown. (B) Cell-cycle analysis of IMR90
cell populations containing empty vector
(V) or H–RasV12 (R) in low-serum condi-
tions. Twenty-four hours postinfection,
cells were transferred to 0.5% FBS-contain-
ing medium, 24 hr later, the cells werepulsed with BrdU for 4 hr; and analyzed for BrdU incorporation and DNA content by two-color
flow cytometry (see Materials and Methods). The box represents cells incorporating BrdU (S-phase); the percentage of BrdU positive
cells are indicated. (C) Representative photomicrographs of IMR90 cells transduced with empty vector or a H–RasV12-expressing
construct. Cells were transduced with retroviruses containing either empty vector or H-RasV12; the photomicrographs were taken at
day 2 postselection (prearrest) and day 4 postselection (postarrest) according to the time scheme described in Materials and Methods.
Figure 2. Effect of Ras-dependent signaling pathways on pro-
liferation. (A) Representative growth curves corresponding to
the indicated IMR90 cell populations containing empty vector
(V, s), H-RasV12 (R, d) H-RasV12/S35 (S, m), H-RasV12/G37
(G, n), H-RasV12/C40 (C, h). Each value was determined in
triplicate and normalized to the cell number at day 0. (B) Rep-
resentative [3H]thymidine incorporation assay of IMR90 cell
populations expressing various Ras-related proteins, Ras effec-
tors or Ras downstream components (see Materials and Meth-
ods). The values were normalized to those obtained from cells
containing a control vector; the average and standard deviation
of three measures are shown.
Lin et al.
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duce cell-cycle arrest. In contrast, cells expressing H–
RasV12/S35 grew slowly, at rates similar to cells ex-
pressing H–RasV12 (Fig. 2A). Of note, each Ras mutant
was expressed at levels equal to (or greater than) H–
RasV12, ranging from a 5- to 10-fold increase over en-
dogenous Ras expression (data not shown). Therefore,
the differential effects of each mutant were not caused
by variations in Ras expression but, more likely, by their
ability to interact with distinct effector proteins. These
results correlate the Ras–Raf interaction with Ras-in-
duced cell-cycle arrest in normal diploid human fibro-
blasts.
Because the Ras effector loop mutants were character-
ized in immortal cell lines, it is formally possible that
they possess different activities in primary cells. As an
alternative approach, selected Ras effectors (Raf-1,
PI(3)K), downstream components (Rac, Akt, RalA, RhoA,
MEK1) (see Introduction), or Ras-related proteins (R-Ras,
TC21) were tested for their ability to cause growth arrest
by retroviral transduction into IMR90 human fibro-
blasts. Of note, R-Ras is highly homologous to H-Ras,
and interacts with PI(3)K and activates the PI(3)K/Akt
pathway but not the MAPK pathway in vivo (Marte et al.
1997). TC21 is more closely related to H-Ras than any
other known member of the Ras superfamily but does
not activate Raf (Graham et al. 1996). Consequently, H-
Ras, R-Ras, and TC21 stimulate cell growth and trans-
formation via distinct signaling pathways. After selec-
tion for virus-infected populations, cells were plated at
subconfluent densities and pulsed with [3H]thymidine in
the presence of 10% serum. Among the Ras effectors and
downstream components examined, some enhanced pro-
liferation, whereas others had little effect (Fig. 2B). Only
constitutively active Raf-1 and MEK—components of
the MAPK cascade—inhibited proliferation (Fig. 2B; see
also Zhu et al. 1998). Neither R-Ras nor TC21 produced
cell-cycle arrest. Therefore, both the Ras mutant and ef-
fector analysis are consistent: Ras-induced arrest in nor-
mal diploid human fibroblasts involves activation of the
MAPK cascade.
Activation of the MEK/MAPK cascade induces p53,
p16, and premature senescence
The MEKs are dual specificity protein kinases that, upon
activation, phosphorylate the threonine and tyrosine
regulatory sites of MAPKs (for review, see Marshall
1994). MEK1Q56P is a MEK mutant identified by virtue of
its ability to enhance the transforming activity of other-
wise transforming-defective Ras mutants. Substitution
of glutamine to proline at codon 56 results in a gain-of-
function mutant that has increased kinase activity (Bot-
torff et al. 1995). To better characterize MEK-induced
arrest, the proliferation properties of IMR90 cell popula-
tions containing a control vector, oncogenic Ras, or
MEK1Q56P were measured by growth curves, or by BrdU-
labeling and flow cytometry (Serrano et al. 1997). Acti-
vated MEK causes arrest even more rapidly than onco-
genic Ras, with cells displaying a dramatic reduction in
BrdU incorporation [compare 0.6% (MEK) and 0.3% (Ras)
to 24.5% (vector) (Fig. 3A,C)]. Likewise, MEK-expressing
cells arrest primarily with a G1 DNA content, although
there is a clear G2 component (Fig. 3C). Importantly,
both oncogenic Ras and MEK1Q56P activate MAPK in
human fibroblasts (Fig. 3B).
The adenovirus E1A oncogene cooperates with ras to
transform primary rodent fibroblasts (Ruley 1990) and
abrogates Ras-induced senescence (Serrano et al. 1997).
To determine the effect of E1A on MEK-induced arrest,
IMR90 cells were infected sequentially with retroviruses
expressing E1A, and then either MEK1Q56P or a control
Figure 3. Activated MEK induces cell-cycle arrest in human
diploid fibroblasts. (A) Representative growth curves corre-
sponding to IMR90 cell populations transduced with empty vec-
tor (V, s), H–RasV12 (R, d), MEK1Q56P (M, m) or
E1A+MEK1Q56P (E1A+M, n). Each value was determined in trip-
licate and normalized to the cell number at day 0. (B) Expression
of ectopic MEK1Q56P in retrovirally infected IMR90 cells was
verified by immunoblot analysis at day 4 postselection. MAP
kinase activity in cell populations at day 2 postselection was
measured by immunoprecipitation of ERK2, followed by a ki-
nase assay using [g-32P]ATP and myelin basic protein as sub-
strate (see Materials and Methods). (C) Cell-cycle analysis of the
indicated cell populations (day 6 postselection) as determined
by BrdU incorporation and DNA-content analysis (see Materials
and Methods). The histogram displays the DNA profile of the
indicated cell population as measured by propidium iodide.
(Insets) The upper box indicates cells incorporating BrdU (S
phase); the lower-left box displays G0/G1 cell population; the
lower-right box indicates cells in G2/M.
MAPK cascade, senescence, and tumor suppression
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vector. Cell populations coexpressing E1A and
MEK1Q56P accumulated at rates comparable to vector-
containing cells and incorporated high levels of BrdU,
showing no signs of cell-cycle arrest (Fig. 3A,C). Conse-
quently, as in the case of Ras-expressing cells, E1A ef-
fectively counters MEK-induced arrest and allows un-
controlled proliferation.
Cellular senescence is accompanied by a series of
changes that, together, distinguish senescence from qui-
escence or differentiation. These changes include altered
expression of cell-cycle proteins, upregulation of p53,
p16, and p21, and the accumulation of senescence-asso-
ciated b-galactosidase (SA-b-gal) (Noda et al. 1994; At-
adja et al. 1995; Dimri et al. 1995; Alcorta et al. 1996;
Reznikoff et al. 1996). Like cells expressing oncogenic
Ras, MEK1Q56P-expressing cells harbored underphos-
phorylated Rb and lost cyclin A expression (Fig 4). Also,
MEK induced p53 (about threefold induction), p21 (about
fivefold induction), and p16 (about sixfold induction)
(Fig. 4). Finally, MEK1Q56P-expressing cells exhibited
high levels of SA-b-gal activity, with a percentage of
positive cells similar to that observed in Ras-expressing
or late passage IMR90 cells (Fig. 5A,B). Of note, these
effects require constitutive MEK activation, because
cells overexpressing a wild-type MEK allele grow nor-
mally, display normal levels of p53, p21, p16, and are
negative for SA-b-gal activity (data not shown).
These data indicate that the cell-cycle arrest produced
by oncogenic Ras and activated MEK is virtually identi-
cal and is characteristic of cellular senescence. Indeed,
the only difference we observed between these popula-
tions is their morphology: Whereas Ras-arrested cells be-
came large and flat, MEK-arrested cells were small and
refractile (Fig. 5A). Nevertheless, MEK-expressing cells
remain arrested in a metabolically active state for as long
as we have observed them (>2 weeks). Because Rho fam-
ily members mediate changes in cell morphology in
other settings (for review, see Van Aelst and D’Souza-
Schorey 1997), they may contribute to the morphological
changes observed in Ras-arrested cells. Nevertheless,
cell morphology has been dissociated from senescence in
other settings (Wistrom and Villeponteau 1990). Thus,
activation of the MAPK cascade is sufficient to promote
premature senescence.
MEK activation is required for premature senescence
To determine whether MEK activity was required for
senescence, we took advantage of PD98059, a highly spe-
Figure 4. Activated MEK induces accumulation of p53 and
p16. Immunoblots of cell-cycle regulatory proteins in lysates
from cells containing empty vector (V), H–RasV12 (R), or
MEKQ56P (M) at day 4 postselection.
Figure 5. MEK activates premature senescence. (A) Photomi-
crographs of IMR90 cell populations containing an empty vector
(V), H–RasV12 (R), or MEK1Q56P (M) stained for SA-b-galactosi-
dase activity (pH 6.0) at day 6 postselection. Late-passage IMR90
cells (LP) having undergone replicative senescence are shown
for comparison. (B) Percentage of cells positive for SA-b-galac-
tosidase 6 days after drug selection. Cells (∼ 200) from each cell
population were scored; the average and standard deviation of
data from at least three separate experiments are shown.
Lin et al.
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cific noncompetitive MEK inhibitor that prevents its ac-
tivation by Raf (Alessi et al. 1995; Dudley et al. 1995).
IMR90 cells were infected with control or oncogenic
Ras-expressing retroviruses, and treated daily with 50 µM
PD98059 prior to the onset of cell-cycle arrest and the
appearance of senescence-related markers (3 days postin-
fection). Notably, this drug concentration has been
found previously to be compatible with the proliferation
of fibroblasts albeit at slower rates (Pumiglia and Decker
1997). All cultures were monitored for proliferation and
senescence as described above.
Remarkably, PD98059 prevented the onset of Ras-in-
duced arrest but had no effect on the accumulation of
vector-containing cells (Fig. 6A). Although the accumu-
lation rate of Ras-expressing cells treated with PD98059
did not achieve that of untreated cells harboring an
empty vector, they displayed an approximately sixfold
increase in BrdU incorporation compared to Ras-express-
ing cells treated with solvent alone (Fig. 6B). Similarly,
treatment with PD98059 prevented the appearance of
the senescence-like morphology and the upregulation of
SA-b-galactosidase in Ras-expressing cells (Fig. 6C).
Moreover, PD98059 had no effect on the detection of
SA-b-gal activity in late passage (senescent) cells, dem-
onstrating that PD98059 does not directly inhibit this
enzyme. Thus, these data imply that MEK—and hence
the MAPK cascade—is required for premature senes-
cence induced by oncogenic Ras.
MEK arrests primary murine fibroblasts
but transforms fibroblasts lacking p53 or p16INK4a
Premature senescence may act as a fail-safe mechanism
that suppresses transformation by Ras (Serrano et al.
1997). Thus, whereas oncogenic Ras arrests primary ro-
dent fibroblasts, it readily transforms primary fibroblasts
lacking p53 or INK4a (Tanaka et al. 1994; Serrano et al.
1996). Because MEK is both necessary and sufficient for
Ras-induced senescence in human fibroblasts, we asked
whether inactivation of p53 or INK4a would overcome
MEK-induced arrest in primary rodent cells. Therefore,
wild-type, p53-null, and INK4a-null primary mouse em-
bryo fibroblasts (MEFs) were infected with control vec-
tor-, Ras-, and MEK1Q56P-expressing retroviruses, and
the rate of cell accumulation was examined in the re-
sulting populations. Of note, our INK4a-null cells have
deletions in INK4a exon 2 that may also inactivate
p19ARF (Haber 1997, see discussion); hence, these cells
are referred to as INK4aex2−/− for clarity.
As in human fibroblasts, MEK promoted cell-cycle ar-
rest in wild-type MEFs (Fig. 7A). However, unlike in hu-
man cells, MEK-arrested MEFs acquired the enlarged and
flat senescent morphology characteristic of Ras-express-
ing MEFs (data not shown). Remarkably, when
MEK1Q56P was expressed at comparable levels in pri-
mary p53−/− and INK4aex2−/− MEFs (Fig. 7B), the result-
ing populations grew at rates similar to parallel cultures
expressing oncogenic Ras, with no indication of a growth
delay or arrest. Moreover, MEK-expressing p53−/− and
INK4aex2−/− MEFs appeared transformed morphologi-
cally (data not shown) and continued to proliferate in
low serum (Fig. 7C). Therefore, deletion of either p53 or
INK4aex2 was sufficient to alter the cellular response to
MEK from permanent arrest to uncontrolled mitogenesis.
The transformation properties of virus-infected popu-
lations were assessed by their ability to grow in suspen-
sion and form tumors in immunocompromised mice. In
soft-agar assays, MEK-expressing populations grown
minimally in culture derived from p53−/− and
INK4aex2−/− cells formed colonies at high frequency (Fig.
7D). Similarly, MEK-expressing populations derived
from p53−/− and INK4aex2−/− MEFs formed tumors at
high frequency when injected subcutaneously into athy-
mic nude mice (Table 1). Importantly, the transforma-
Figure 6. MEK is required for Ras-induced cell-
cycle arrest and premature senescence. (A) Repre-
sentative growth curves documenting the effects
of PD98059 on Ras-induced growth arrest. IMR90
cells were infected with an empty vector- or an
H-RasV12-expressing retrovirus. Immediately af-
ter selection, cell populations were treated daily
with medium containing 50 µm PD98059 or
0.25% DMSO (carrier). Each value was determined
in triplicate and normalized to the cell number at
day 0. (B) Cell populations containing an empty
vector (V) or expressing H-RasV12 (R) were treated
daily with PD98059 (PD). On day 6 postselection,
cells were pulsed with BrdU and analyzed for BrdU
incorporation by flow cytometry. The calculated
percentage of BrdU-positive cells is shown. (C)
Photomicrographs of control and PD98059-treated
cell populations stained for SA-b-gal activity on
day 6 postselection. The percentage of posi-
tive cells in each population was 9% (vector);
12.5% (vector + PD98059); 80% (Ras); 15.4%
(Ras + PD98059); 90% (late passage); 91% (late
passage + PD98059).
MAPK cascade, senescence, and tumor suppression
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tion properties of MEK-expressing cells required coop-
eration between MEK and loss of either p53 (see also
Fukasawa and Vande Woude 1997) or INK4aex2, because
p53−/− and INK4aex2−/− MEFs harboring an inert vector
neither grew in soft agar nor formed tumors in nude
mice. However, MEK1Q56P was not as potent as onco-
genic Ras in transforming p53−/− and INK4aex2−/− MEFs,
because both soft-agar colonies and tumors expressing
MEK were typically smaller than those expressing onco-
genic Ras (Fig. 7D; Table 1). The inability of activated
MEK to recapitulate the potency of oncogenic Ras in
transformation assays is consistent with previous stud-
ies showing that multiple effector pathways contribute
to Ras-mediated transformation (White et al. 1995).
These data demonstrate that activated MEK efficiently
transforms primary MEFs lacking p53 or INK4aex2, cells
otherwise predisposed to immortalization. Because these
MEK-expressing cell populations were derived from pri-
mary fibroblasts grown minimally in culture, it seems
highly unlikely that additional factors contribute to the
transformed phenotype of these cells. Similarly, we
show that human fibroblasts expressing an immortaliz-
ing oncogene (i.e., E1A) overcome MEK-induced arrest.
Together, these data demonstrate that constitutive acti-
vation of the MEK/MAPK cascade can produce either
premature senescence or forced mitogenesis depending
on the integrity of a senescence program controlled by
p53 and p16. The precisely opposite response of primary
and immortal cells to MEK activation implies that pre-
mature senescence is a cellular fail-safe mechanism that
suppresses the transforming potential of aberrant Ras
mitogenic signaling.
Discussion
Oncogenic Ras transforms immortal rodent fibroblasts,
in part, by constitutively transmitting mitogenic signals
through the MAPK cascade. By marked contrast, onco-
genic Ras acutely activates senescence in primary fibro-
blasts through the p53 and p16 tumor suppressors (Ser-
rano et al. 1997). Here we demonstrate that Ras signals
premature senescence through activation of the MAPK
cascade. In normal diploid human fibroblasts, Ras effec-
tor loop mutants that retain their ability to bind Raf-1
promoted premature senescence and, among a series of
Ras downstream components examined, only activated
MEK was capable of inducing p53, p16, and features of
Table 1. Tumorigenicity assays
MEF genotypea
Tumor
frequencyb
Tumor
volumec (cm3)
WT (V) 0/4 N.A.
WT (R) 0/10 N.A.
WT (M) 0/4 N.A.
p53−/− (V) 0/8 N.A.
p53−/− (R) 8/8 1.40 ± 0.66
p53−/− (M) 7/8 0.11 ± 0.087
INK4aex2−/− (V) 0/8 N.A.
INK4aex2−/− (R) 8/8 1.34 ± 1.29
INK4aex2−/− (M) 7/8 0.21 ± 0.11
aPrimary MEFs were isolated from wild-type (WT), p53-defi-
cient (p53−/−), and p16-deficient (INK4aex2−/−) mice and infected
with control vector (V), H-RasV12 (R), or MEK1Q56P (M).
bNumber of tumors arising per number of sites injected.
cTumor volume measured at 2 weeks [V = (L × W2)/2].
Figure 7. Inactivation of either p53 or INK4aex2 reveals
the mitogenic and transforming activity of activated MEK.
(A) Representative growth curves corresponding to wild-
type (WT), p53-null (p53−/−) or p16-null (INK4aex2−/−) MEFs
transduced with empty vector (V), H-RasV12 (R), or
MEK1Q56P (M) expressing retroviruses. Each value was de-
termined in triplicate and normalized to the cell number at
day 0. (B) MEK1 expression in the indicated cell populations was determined by immunoblotting on day 4 postselection. (C) [3H]thy-
midine incorporation in the indicated cell populations containing empty vector (gray bars) or MEK1Q56P (black bars). On day 6
postselection, cells were transferred to 0.5% FBS-containing medium for 36 hr, followed by a 24-hr pulse with [3H]thymidine. Each
value was determined in triplicate and normalized to the value obtained for wild-type cells containing the empty vector. (D) Analysis
of anchorage-independent growth of the indicated MEF populations. Immediately following selection for virus-transduced populations,
∼2 × 14 cells were plated in soft agar (see Materials and Methods). Photomicrographs were taken 3 weeks after plating.
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senescence. Moreover, a MEK inhibitor prevented Ras-
induced cell-cycle arrest and senescence. In primary mu-
rine fibroblasts, activated MEK arrested wild-type MEFs
but forced uncontrolled mitogenesis and transformation
when expressed at comparable levels in p53−/− or
INK4aex2−/− MEFs. Thus, oncogenic Ras arrests normal
cells through the primary mechanism whereby it trans-
forms immortal cells or primary fibroblasts defective in
p53 or p16 function.
Role of the MAPK cascade in cell-cycle arrest
Signaling through the MAPK cascade is relevant to sev-
eral physiological processes, including mitogenesis, dif-
ferentiation, and even apoptosis, depending on the cel-
lular context (for review, see Marshall 1998). In some
settings, the difference between proliferation and arrest
is related to the intensity or duration of the signal (Sew-
ing et al. 1997; Woods et al. 1997; Kerkhoff and Rapp
1998). We show that oncogenic Ras initially forces un-
controlled proliferation, and only later do cells arrest.
Importantly, the cell-cycle arrest induced by expression
of Ras or MEK is abolished in cells expressing E1A
(IMR90), or lacking p53 or p16 (MEFs). In contrast to our
observations, others have found that high levels of Raf
activity can produce an immediate cell-cycle arrest that
occurs independently of p53 or p16 (Sewing et al. 1997;
Woods et al. 1997). Perhaps the difference between these
studies and ours reflects the fact that other Ras effector
pathways can attenuate Raf-induced arrest and impinge
upon its ability to activate components of the arrest ma-
chinery (Olson et al. 1998); alternatively, they may arise
from different levels and kinetics of activation of the
Raf/MAPK cascade. Nevertheless, the results presented
here demonstrate clearly that Ras-mediated MAPK acti-
vation can produce two precisely opposite outcomes—
cell-cycle arrest or forced mitogenesis—depending on
the integrity of the senescence program controlled by
p53 and p16.
Other mitogenic oncogenes can display antiprolifera-
tive potential. For example, the c-myc and E1A onco-
genes induce proliferation, but both activate p53 to pro-
mote apoptosis (for review, see Weinberg 1997). The Myc
functions involved in both proliferation and apoptosis
are related (Evan et al. 1992; Amati et al. 1993) and, at
least in primary cells, the E1A domains required for p53
accumulation, apoptosis, and oncogenic transformation
are inseparable (Samuelson and Lowe 1997). The fact
that oncogenic Ras uses the same signal-transduction
pathway to promote both arrest and forced mitogenesis
reinforces the view that normal cells counter malignant
transformation by actively responding to hyperprolifera-
tive signals; in this case, by sensing excessive MEK/
MAPK activity and activating senescence. The necessity
to overcome these fail-safe mechanisms can explain the
phenomenon of oncogene cooperation and may be im-
portant during multistep carcinogenesis.
The MAPK cascade and senescence
The cell-cycle arrest induced by deregulated MEK activ-
ity in primary fibroblasts reflects bona fide cellular se-
nescence and not an unusual form of quiescence or dif-
ferentiation. First, unlike quiescence, both oncogenic
Ras and MEK arrest cells at subconfluent densities in the
presence of mitogenic growth factors. This arrest is per-
manent: whereas the MEK inhibitor PD98059 prevents
Ras-induced arrest when added prior to the appearance of
senescence markers, it cannot reverse the arrest at later
times (data not shown). Second, although p53 and p16
play fundamental roles in Ras-induced arrest, neither
have essential roles in differentiation. Indeed, most p53-
and INK4aex2-deficient mice develop normally (Done-
hower et al. 1992; Serrano et al. 1996). Cell-cycle arrest
induced by Ras and MEK is accompanied by accumula-
tion of p53, p21, p16, and SA-b-gal activity. Importantly,
these markers together are associated with cellular se-
nescence in both fibroblasts and epithelial cells but
rarely, if ever, with quiescence or differentiation (Atadja
et al. 1995; Dimri et al. 1995; Palmero et al. 1997). Fi-
nally, cDNA array analysis of ras-arrested fibroblasts re-
veals global changes in gene expression consistent with
that reported for senescent cells (G. Ferbeyre and S.W.
Lowe, unpubl.).
The characterization of Ras-induced arrest in primary
fibroblasts as cellular senescence, and the involvement
of the MEK/MAPK cascade in this process, have impor-
tant implications for our understanding of senescence
biology. Senescence was defined originally by the obser-
vation that primary cells have a genetically determined
limit to their proliferative potential in cell culture, after
which they arrest permanently with characteristic fea-
tures (Hayflick 1965). Owing to the ‘end-replication
problem’, telomeres shorten during each cell division
unless telomerase is expressed, and it has been proposed
that some aspect of excessive telomere shortening acti-
vates cell-cycle arrest and other characteristics of senes-
cence (for review, see Greider 1998). However, a number
of exogenous stimuli can also produce a phenotype sug-
gestive of senescence, including DNA damage, DNA-de-
methylating drugs, ceramide, or inhibitors of histone
deacetylation (Holliday 1986; Venable et al. 1995; Ogry-
zko et al. 1996; Linke et al. 1997), raising the possibility
that telomere shortening is not the only signal capable of
activating the senescence program.
Our data demonstrate that senescence can be activated
in response to deregulated MAPK activation through
MEK. Consistent with these results, forced Raf-1 expres-
sion also activates senescence in normal human fibro-
blasts (see Fig. 2B; Zhu et al. 1998). Whereas it remains
possible that telomere shortening or some other cell-
doubling-sensitive mechanism activates senescence
through Ras/MAPK signaling, our hypothesis is that se-
nescence can be activated by diverse stimuli leading to
engagement of a common cell-cycle arrest program. In
this view, the process of senescence is related conceptu-
ally to apoptosis, a genetically controlled program car-
ried out by a common cell-death machinery. Diverse
stimuli and signaling pathways feed into this machinery,
allowing regulation of cell death to be highly versatile.
Although less understood, the possibility that multiple
MAPK cascade, senescence, and tumor suppression
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signaling pathways induce senescence is consistent with
cell fusion studies (for review, see Vojta and Barrett
1995). Consequently, the biological roles of cellular se-
nescence may go well beyond the control of cellular or
organismal aging, acting as a global anti-proliferative re-
sponse to a variety of cellular stresses.
The role of p16 and p53 in premature senescence
The precise role of p16 in tumor suppression is con-
founded by the complexity of the INK4a locus, which
encodes a second tumor suppressor translated in an al-
ternative reading frame designated p19ARF (Quelle et al.
1995). Mutations at the INK4a locus often disrupt both
p16 and p19ARF (for review, see Haber 1997) and mice
lacking p19ARF develop tumors (Kamijo et al. 1997).
p19ARF also promotes cell-cycle arrest and primary cells
derived from ARF-deficient mice can be transformed by
oncogenic Ras alone (Kamijo et al. 1997). Because the
mutation in our INK4aex2−/− MEFs may disrupt p19ARF
function, it is possible that p19ARF is the sole product of
the INK4a/ARF locus responsible for senescence in re-
sponse to oncogenic Ras. Oncogenes can signal p53
through p19ARF (Zindy et al. 1998; de Stanchina et al.
1998); moreover, oncogenic Ras and MEK induce ARF
message and protein and ARF-null MEFs are defective in
Ras-induced arrest (Palmero et al. 1998; G. Ferbeyre,
A.W. Lin, F. Zindy, M. Roussel, C.J. Sherr, and S.W.
Lowe, unpubl.). Nevertheless, p16 contributes to Ras-
induced senescence. For example, p16 accumulates in
response to oncogenic Ras and MEK, and expression of a
p16-insensitive Cdk4 mutant (R24C) (Wolfel et al. 1995)
counters Ras-induced growth arrest (Serrano et al. 1997).
Furthermore, in human cells, p16 can directly induce
senescence (Uhrbom et al. 1997; McConnell et al. 1998)
and can be inactivated spontaneously during the immor-
talization process (Reznikoff et al. 1996; Foster et al.
1998). Regardless of the relative contribution of p16 and
p19ARF to this process, the INK4aex2-deficient cells used
accurately recapitulate mutations in human tumors.
In rodent cells, the cell-cycle arrest induced by acti-
vated MEK is abrogated by inactivation of either p53 or
p16 (Fig. 7; see also Serrano et al. 1997). Nevertheless,
p53 and p16 do not function in a simple linear pathway.
p16 levels increase in response to Ras in p53−/− MEFs
and, conversely, p53 levels increase in INK4aex2−/− MEFs
(data not shown). Introduction of oncogenic Ras or MEK
into INK4aex2−/−;p53−/− double-mutant MEFs produces
more transformed foci than in either single mutant
(A.W. Lin and S.W. Lowe, unpubl.). Thus, p53 and p16
(and perhaps p19ARF) act cooperatively to promote Ras-
induced arrest, and disruption of either p53 or p16 pre-
vents arrest and is sufficient for transformation. In hu-
man cells, p53 and p16 also appear to cooperate to pro-
mote arrest, although inactivation of both pathways
appears necessary to escape senescence (see discussion in
Serrano et al. 1997). Consistent with this view, ectopic
expression of p21 (a p53 target) and p16 can induce se-
nescence in human cells (McConnell et al. 1998; Vogt et
al. 1998).
The activation of p53 and p16 in response to deregu-
lated MEK/MAPK signaling provides a relevant setting
in which these tumor suppressors act to limit malignant
transformation. In this view, mutations that deregulate
the MAPK cascade provide an initial proliferative advan-
tage but also accelerate senescence. However, cells ac-
quiring mutations in p53 or at the INK4a/ARF locus
escape senescence, thereby revealing the full mitogenic
potential of the MAPK cascade. Consistent with this sce-
nario, ras mutations often precede mutations in p53 or
INK4a during tumor development (Fearon and Vogel-
stein 1990; Burns et al. 1991; Linardopoulos et al. 1995).
Premature senescence and tumor suppression
In summary, our data demonstrate that oncogenic Ras
promotes premature senescence through activation of
the MAPK cascade. Remarkably, this is the same path-
way whereby Ras induces mitogenesis in immortal cells.
Escape from Ras-induced senescence allows inappropri-
ate proliferation and, in rodent cells, oncogenic transfor-
mation. Consequently, the biological outcome of consti-
tutive MAPK activation—cell-cycle arrest or forced mi-
togenesis—is largely context-dependent and determined
by the integrity of the senescence machinery. These data
strongly support the notion that normal cells possess
fail-safe mechanisms that limit the consequences of Ras
mitogenic signaling. Because these safeguards involve
p53 and p16, the activation of premature senescence in
response to forced mitogenic signaling may be an impor-
tant mechanism of tumor suppression.
Materials and methods
Cell culture
Normal diploid human IMR90 fibroblasts (early–mid passages)
expressed the murine ecotropic receptor (Serrano et al. 1997),
and primary mouse embryo fibroblasts derived from wild-type,
p53−/− and INK4aex2−/− day 13.5 embryos were prepared as de-
scribed previously (Jacks et al. 1994; Serrano et al. 1997). All
cultures were maintained in Dulbecco’s modified Eagle me-
dium (DMEM; GIBCO) supplemented with 10% fetal bovine
serum (FBS; Sigma) and 1% penicillin G/streptomycin sulfate
(Sigma).
Retroviral vectors and gene transfer
Oncogenic Ras (H–RasV12) (Serrano et al. 1997) and Ras effector
loop mutants (White et al. 1995; Joneson et al. 1996) were ex-
pressed using the pBabe–Puro vector (Morgenstern and Land
1990). cDNA encoding Rac1 (N115I), RalA, RhoA (Q63L), R–
Ras (G38V), TC21 (Q72L), PI(3)Kp110a (K227E), PI(3)Kp110a–
CAAX, wild-type Akt, or E1A12S, respectively, were cloned
into a pLPC retroviral vector. Raf-1–CAAX was cloned into a
Babe–Puro retroviral vector. MEK1Q56P (Bottorff et al. 1995) was
expressed using Babe–Puro- or WZL–Hygro-based retroviral vec-
tors (Ariad Pharmaceuticals, unpubl.). Retroviral gene transfer
was performed as described (Serrano et al. 1997) using high-titer
retroviral stocks generated by transient transfection of the
Phoenix ecotropic packaging line (G. Nolan, Stanford Univer-
sity, CA). Infected cell populations were selected by culture in
puromycin (2.5 µg/ml, 3 days) or in hygromycin (200 µg/ml, 5
days) to eliminate uninfected cells. Day 4 postinfection was
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designated as day 0 (Serrano et al. 1997). In all experiments, cells
infected with an empty vector were used as control.
Analysis of cell proliferation
Cell proliferation was assessed by three criteria: growth curves,
[3H]thymidine incorporation and flow cytometry of BrdU-la-
beled cells. For growth curves, cells were plated at a density of
2.5 × 104 per well in 12-well-plates following drug selection.
Cells were fixed in 10% formalin at the indicated times accord-
ing to a time scheme and method described previously (Serrano
et al. 1997). Crystal violet (0.1%; Sigma) was used to stain cells.
Cell-associated dye was extracted in 2 ml of 10% acetic acid and
the optical density was measured at 590 nm with each value
normalized to day 0. Each point was done in triplicate, each
growth curve was performed at least twice. For experiments
using PD98059 (Calbiochem), treatment was initiated 2 days
postinfection. Cells were fed daily with fresh medium contain-
ing 50 µM PD98059 containing 0.25% DMSO. Solvent-contain-
ing medium was used to treat control cultures in parallel.
For [3H]thymidine incorporation assay, 2 × 104 cells per well
in 12-well-plates were plated in triplicate. Cells were pulsed for
20–24 hr or 4 hr with 5 µCi/ml [methyl-3H]thymidine (Amer-
sham, 2 Ci/mmoles). After washing with PBS, cells were tryp-
sinized and transferred to glass fiber filters (Filtermat, Wallac)
followed by scintillation counting. For BrdU incorporation and
DNA-content analysis, subconfluent cultures were labeled with
10 µM BrdU (Amersham) for 4 hr. Cells were trypsinized and
fixed in 75% ethanol for 30 min. Cells were washed in PBS and
were treated subsequently with 2 M HCl for 20 min at room
temperature. After washing in washing buffer (0.1% BSA/PBS),
cells were neutralized in 0.1 M sodium borate for 2 min followed
by washing in washing buffer. Cells were incubated subse-
quently with FITC-conjugated anti-BrdU antibody (Pharmin-
gen) for 1 hr at room temperature or overnight at 4°C. Finally,
cells were washed in washing buffer three times followed by
treatment with propidium iodide (10 µg/ml) and RNase A (100
µg/ml) at 37°C for 30 min. Samples were analyzed by two-di-
mensional flow cytometry to detect both fluorescein and prop-
idium iodide.
Protein expression and activity
Western blot analysis was carried out as described previously
with minor modifications (Serrano et al. 1997). Whole-cell ly-
sates were derived by lysing cell pellets in Laemmli SDS sample
buffer. Samples corresponding to 30 µg of protein were resolved
on SDS-PAGE gels and transferred to immobilone-P membranes
(Millipore). The following antibodies were used: CM1 (Novo-
castra) at 1:1000 dilution for the detection of p53, anti-
WAF1(p21) antibody (C-19; Santa Cruz) at 1:500 dilution, anti-
p16 antibody (DCS-50; Novocastra) at 1:200 dilution, anti-Rb
(G3-245; Pharmingen) at 0.5 µg/ml together with C-36 and XZ-
55 hybridoma supernatant at 1:100 dilution each. Anti-cyclin A
(Santa Cruz) at 1:500 dilution. Anti-Ras antibody (Santa Cruz) at
1:500 dilution. Western blot analysis was accomplished accord-
ing to standard procedures using ECL detection (Amersham).
For MAPK assays, cells were lysed in lysis buffer (20 mM
Tris-HCl at pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA,
1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM b-glyc-
erolphosphate, 1 mM Na3VO4, 1 µg/ml leupeptin, 1 mM PMSF)
accompanied by brief sonication on ice. Protein lysate (100 µg)
was incubated with a polyclonal antibody against ERK2 (1:50
dilution; Santa Cruz) for 3 hr at 4°C. Afterwards, 25 µl of protein
A–Sepharose beads (50%) were added to the mixture and were
incubated for another 3 hr at 4°C. Samples were washed subse-
quently and resuspended in 20 µl of kinase buffer (25 mM Tris-
HCl at pH 7.5, 10 mM MgCl2, 5 mM b-glycerolphosphate, 2 mM
DTT, 0.1 mM Na3VO4) supplemented with 10 µCi [g-
32P]ATP
(3000 Ci/mmoles) and 5 µg of myelin basic protein (MBP;
Sigma) and the reaction mixtures were incubated at 30°C for 30
min. The samples were resolved on 12% SDS–polyacrylamide
gels and exposed to Kodak X-OMAT AR.
SA-b-galactosidase activity was detected as described previ-
ously (Dimri et al. 1995) with minor modifications. Cells were
washed with PBS, fixed in 0.5% glutaraldehyde, and were incu-
bated with staining solution [1 mg/ml 5-bromo-4-chloro-3-in-
dolyl b-galactoside (X-gal), 5 mM potassium ferrocyanide, 5 mM
potassium ferricyanide, 1 mM MgCl2 in PBS at pH 6.0] for ∼12 hr
at 37°C.
Transformation assays
For soft-agar assays, cells were resuspended in 0.3% Noble agar
(in DMEM supplemented with 10% FBS) at a density of 2 × 104
cells per well (in six-well plates), and were plated onto solidifed
0.5% Noble agar-containing bottom layer medium. Cultures
were fed weekly and photomicrographs of colonies were taken 3
weeks postplating. Experiments were repeated twice, and MEFs
from two different embryo preparations were used in each assay.
For in vivo tumorigenicity assays, 106 cells/0.25 ml of PBS
were injected subcutaneously into male NSW athymic nude
mice (Tatonic Farms). Each animal received two injections, one
on each rear flank. Virus-infected MEFs from two different em-
bryo preparations were used for each genotype, and at least two
animals were examined for each cell population (i.e., four tu-
mors). Tumor formation was monitored three times per week
by palpation at the sites of injection. The length (L) and width
(W) of tumors were measured using a caliper and the volume of
tumor formed was determined using the formula V = (L × W2)/2.
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